RNA‐Peptide nanoplexes drug DNA damage pathways in high‐grade serous ovarian tumors

Bioengineering & Translational Medicine

  ^{1    2    2    2    3    3    3    4    5    5    5    5    6    7} 

[1] Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;Dept. of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;Dept. of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139;Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;Dept. of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139;Dept. of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;Div. of Acute Care Surgery, Trauma, and Surgical Critical Care, Dept. of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215;Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;Dept. of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;Dept. of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139;Institute for Soldier Nanotechnologies, Massachusetts Institute of Technology, Cambridge, MA 02139;Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139;Dept. of Obstetrics, Gynecology, and Reproductive Biology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215;

关键词: chemosensitization;    DNA damage;    nanomedicine;    ovarian cancer;    polymer engineering;    RNA interference;   

DOI  :  10.1002/btm2.10086

来源: publisher

【 授权许可】

Unknown